Literaturverzeichnis Prof. Dr. med. R. Kimmig Originalarbeiten ...

Literaturverzeichnis
Prof. Dr. med. R. Kimmig
Originalarbeiten,
Übersichten
und Buchbeiträge
1. Kimmig R, Mauch TJ, Kerzl W, Schwabe U, Scholz R.
Actions of glucagon on flux rates in perfused rat liver. 1. Kinetics of the inhibitory
effect on glycolysis and the stimulatory effect on glycogenolysis.
Eur J Biochem (1983) 15;136(3):609-16
2. Kimmig R, Mauch TJ, Scholz R.
Actions of glucagon on flux rates in perfused rat liver. 2. Relationship between
inhibition of glycolysis and stimulation of respiration by glucagon.
Eur J Biochem (1983) 15;136(3):617-20
3. Kimmig R.
Über die Kurzzeitregulation des Leberstoffwechsels durch Glucagon: Wirkungen
auf Glykogenolyse, Glykolyse, Sauerstoffverbrauch und Ketogenese, Kinetiken
der direkten und indirekten Glucagoneffekte, Interaktionen der Stoffwechselprozesse
im ―transient‖ und im ―steady state‖, untersucht in der isolierten,
nichtrezirkulierend perfundierten Rattenleber.
Inauguraldissertation an der Ludwig-Maximillians-Universität München. (1986)
4. Hartl WH, Jauch KW, Kimmig R, Wicklmayr M, Gunther B, Heberer G.
Minor role of ketone bodies in energy metabolism by skeletal muscle tissue during
the postoperative course.
Ann Surg (1988);207(1):95-101
5. Jochmus-Kudielka I, Schneider A, Braun R, Kimmig R, Koldovsky U, Schneweis
KE, Seedorf K, Gissmann L.
Antibodies against the human papillomavirus type 16 early proteins in human sera:
correlation of anti-E7 reactivity with cervical cancer.
J Natl Cancer Inst (1989);81(22):1698-1704
6. Pfeiffer DG, Ritz P, Kimmig R, Mann K, Scheidel P.
EGF and TGF-beta: effects on growth and on the secretion of beta-HCG in
cervical carcinoma cells.
Acta Endo (1989);120 (S):145-146
7. Luppa P, Neumeier D, Kimmig R.
Rationelle Labordiagnostik des Hyperandrogenismus der Frau.
Ärztl Lab (1989);35:247-52
8. Kimmig R, Egner D, Spelsberg H, Untch M, Kapsner Th.
Durchflußzytometrische DNA-Analyse bei Mammakerzinomen: Korrelaton mit
klinischen Prognosefaktoren. Arch Gynecol Obstet (1991);250: 209-210

9. Strowitzki T, Wiedemann R, Kimmig R, Hepp H.
Einfluß von EGF, IGF-1 und Wachstumshormon auf endometriale Stromazellen in
vitro.
Arch Gynecol Obstet 250: (1991) 1015-1016
10. Gerhard I, Schindler AR, Bühler K, Winkler U, Meinen K, Mancella D, Hoffmann G,
Schüssler B, Kimmig R, Kranzfelder D.
Treatment of endometriosis with leuprorelin acetate depot: a German multicentre
study.
Clin Ther (1991);14 Suppl A:3-16
11. Kimmig R.
Standardlagerungen: Buchbeitrag in: Hepp H, Scheidel P, Schüßler B,
Gynäkologische Standardoperationen.
Ferdinand Enke, Stuttgart (1991):373-8
12. Kimmig R, Hasbargen U, Hepp H.
Hysteroskopisches Staging des Endometriumkarzinoms.
(zum Beitag: R. Schild, Th. Kutter. Geburtsh. und Frauenheilk. 52 (1992) 467-
470).
Geburtshilfe und Frauenheilkunde:(1993);53 433-434
13. Gerhard I, Schindler AE, Buhler K, Winkler U, Meinen K, Mancarella D, Hoffmann
G, Schussler B, Kimmig R, Kranzfelder D.
Treatment of endometriosis with leuprorelin acetate depot: a German multicentre
study.
Clin Ther (1992);14 Suppl A:3-16
14. Kimmig R, Untch M, Pfeiffer D, Egner D, Strowitzki T, Hepp H.
Multiparametric flow cytometry determination of the EGF receptor and DNA cell
cycle distribution in cervix cancer.
Gynäkol Geburtsh. Rundsch (1993);33 Suppl 1:283-4
15. Untch M, Nestle-Kramling C, Konecny G, Harbeck N, Funke I, Kimmig R, Hepp H.
Prognostic value of tumor cells in bone marrow in breast cancer.
Gynäkol Geburtsh. Rundsch (1993);33 Suppl 1:308-10
16. Kimmig R, Hasbargen U, Hepp H.
Hysteroscopic staging of endometrial cancer. Comment on the contribution by R.
Schild, Th. Kutter
Geburtshilfe und Frauenheilkunde (1993);53(6):433-4
17. Kimmig R, Pfeiffer D, Pfeiffer A, Hepp H.
Bestimmung des EGF-Rezeptors zur Prognoseeinschätzung des Zervixkarzinoms.
Arch Gynecol Obstet (1993);254:1028-30
18. Kimmig R.
Nafarelin – GnRH-Agonist zur Behandlung der Endometriose.
Arzneimittelther (1993);11:145-7
19. Kimmig R.
Metergolin – ein hypophysärer Dopaminagonist.
Arzneimittelther (1993);11:143-4

20. Kimmig R, Ratzel R.
Eigenblutspende in Gynäkologie und Geburtshilfe. Stellungnahme der Deutschen
Gesellschaft für Gynäkologie und Geburtshilfe.
Der Frauenarzt (1993);34:606-7
21. Schindler AE, Buhler K, Gerhard I, Wiedemann R, Kimmig R, Schussler B,
Kranzfelder D, Mall-Hafeli M, Meinen K, Mancarella D, et al.
Treatment of endometriosis with the GnRH agonist leuprorelin acetate depot
(Enatone-Gyn monthly depot): a multicenter study.
Zentralbl Gynäkol (1994);116(12):679-86
22. Kimmig R, Klocke G, Hepp H.
Requirements in preoperative diagnosis of gynecologic diseases of the pelvis
Radiologe (1994);34(7):346-50
23. Kimmig R, Spelsberg H, Kapsner T, Untch M, Hepp H.
Flow cytometric DNA analysis of breast cancer by two colour method using
cytokeratin labeling for identification of tumour cells.
Anal Cell Pathol (1994);7(3):205-15
24. Schindler AE, Bühler K, Gerhard I, Wiedemann R, Kimmig R, Schüssler B,
Kranzfelder D, Mall-Häfeli M, Meinen K, Mancarella D, Hofmann G.
Behandlung der Endometriose mit dem GnRH-Agonisten Leuprorelinacetat Depot
(Enantone Gyn Monats-Depot): Eine multizentrische Studie.
Zentralbl Gynäkol (1994);116:679-86
25. Webster J, Piscitelli G, Polli A, Ferari Cl, Ismail I.
Scanlon MF fort he Cabergonline Comparative Study Group*,*…R. Kimmig and
O.A. Muller, Munich, Germany; …. Cabergoline versus bromodcriptine in the
treatment of hyperprolactinemic amenorrhea.
New Engl J Med (1994);331:904-09
26. Kürzl R, Kimmig R, Schürmann H.
(Redaktion) für die Projektgruppe Zervix- und Endometriumkarzinom des
Tumorzentrums München. Manual: Endometriumkarzinom. Empfehlung zur
Diagnostik, Therapie und Nachsorge, Tumorzentrum München (1994).
27. Kimmig R, Egner D, Hepp H.
Durchflußzytometrische DNS-Analyse maligner epithelialer gynäkologischer
Tumoren. In: Tumorimmunologie in der Gynkökologie (Koldovsky U, Kreienberg R,
Hrsg.)
Zuckschwerdt Verlag München Bern Wien New York (1994) S. 124-31
28. Kimmig R, Seehaus D, Scheidel P, Hepp H.
Krebserkrankungen – hormonelle Substitution – orale Kontrazeption.
Kongresszeitung 50. Kongreß der Deutschen Gesellschaft für Gynäkologie und
Geburtshilfe (1994) S. 12-14
29. Kimmig R, Kapsner T, Spelsberg H, Untch M, Hepp H.
DNA cell-cycle analysis of cervical cancer by flow cytometry using simultaneous
cytokeratin labeling for identification of tumor cells.
J Cancer Res Clin Oncol (1995);121(2):107-14

30. Kimmig R, Klocke G und Hepp H.
Erfordernisse der präoperativen Diagnostik bei gynäkologischen Erkrankungen im
kleinen Becken.
Radiologie (1994);34:346-50
31. Kimmig R, Kürzl R, Höß C, Landsmann H.
(Redaktion) für die Projektgruppe Zervix- und Endometriumkarzinom des
Tumorzentrums München. Manual: Zervixkarzinom: Empfehlungen zur Diagnostik,
Therapie und Nachsorge, Tumorzentrum München (1994)
32. Kimmig R, Seehaus D, Scheidel P, Hepp H.
Hormonal replacement therapy and oral contraception. Risk of induction or
reactivation of gynecologic malignancies.
Gynäkol Geburtshilfliche Rundsch (1995);35(2):72-8
33. Luppa P, Muller B, Jacob K, Kimmig R, Strowitzki T, Hoss C, Weber MM,
Engelhardt D, Lobo RA.
Variations of steroid hormone metabolites in serum and urine in polycystic ovary
syndrome after nafarelin stimulation: evidence for an altered corticoid excretion.
J Clin Endocrinol Metab (1995);80(1):280-8
34. Kimmig R.
Hysteroscopic surgery.
Arch Gynecol Obstet (1995);257(1-4):21-9
35. Gerber B, Krause A, Kimmig R.
Immunohistologic tumor cell detection in lymph nodes in node negative breast
cancer: correlation with "established" and "recent" prognostic factors.
Gynäkol Geburtsh. Rundsch (1995);35 Suppl 1:32-5
36. Kimmig R, Strowitzki T, Muller-Hocker J, Kurzl R, Korell M, Hepp H.
Conservative treatment of endometrial cancer permitting subsequent triplet
pregnancy.
Gynecol Oncol (1995);58(2):255-7
37. Kimmig R, Landsmann H, Fileki M, Spelsberg H, Untch M, Kapsner T.
DNS-Zellzyklusanalyse beim Mammakarzinom nach Zytokeratinmarkierung zur
Identifizierung der Tumorzellen. Buchbeitrag in: Aktuelle Onkologie Band 86,
Aktuelle Aspekte der Tumorimmunologie in der Gynäkologie (Kreienberg R, Grill
HJ, Möbus V, Koldovsky U; Hrsg.).
Zuckschwerdt Verlag München Bern Wien New York (1995), S. 251-9
38. Kimmig R, Seehaus D, Scheidel P, Hepp H.
Hormonelle Substitution und orale Kontrazeption. Risiko der Induktion oder
Reaktivierung gynäkologischer Malignome.
Gynäkol Geburtsh. Rundsch (1995);35:72-8
39. Kimmig R, Knitza R (Hrsg.), Hepp F, Klocke G, Wagner C.
Gynäkologie pur, die Karteikarten
Börm Bruckmeier Verlag GmbH, Grünwald (1995)
40. Kimmig R, Knitza R (Hrsg.), Hepp F, Klocke G, Wagner C.
Gynäkologie pur, das Skript
Börm Bruckheimer Verlag GmbH, Grünwald (1995)

41. Kirschstein M, Untch M, Korell M, Hillemanns P, Kimmig R.
Durchflußzytometrische Untersuchungen zur Wirkungen von delta-
Aminolaevulinsäure (ALA) und Photodynamische Lasertherapie (PDT) auf den
Zellzyklus von Zervixkarzinomzellen.
Laser in der Medizin, Springer Heidelberg (1995), 254-8
42. Kimmig R.
Cabergolin – Ein neuer hypophysärer Dopamingonist.
Arzneimittelther (1995);13: 222-3
43. Kimmig R.
Hysteroskopische Chirurgie.
Arch Gynecol Obstet (1995);257:21-9
44. Gutschow K, Kimmig R.
Hormonsubstitution und gynäkologische Malignome, Krebsrisiko – Lebensqualität.
Krebs (1995);14:49-54
45. Regidor PA, Schindler AE, Buhler K, Gerhard I, Kimmig R, Meinen K, Hoffmann
G, Lubben G, Kienle E.
Results of long-term follow-up in treatment of endometriosis with the GnRH
agonist leuprorelin acetate depot (Enantone-Gyn monthly depot).
Zentralbl Gynäkol (1996);118(5):283-90
46. Romisch M, Meier W, Kimmig R, Hepp H.
13-cis retinoic acid and interferon-alfa-2a as palliative therapy in pretreated,
recurrent squamous epithelial carcinoma of the cervix uteri and vulva.
Geburtshilfe Frauenheilkunde (1996);56(10):520-4
47. Kimmig R.
Diagnostik Gonadeninsuffizienz und Therapie Östogene in: Empfehlungen zu
Prävention, Diagnostik und Therapie der Osteoporose. (Hrsg: E. Senn, B. Busch)
Manual der Arbeitsgruppe Osteoporose der Ludwig-Maximilians-Universität
München, 2. Auflage (1996)
48. Scheidler J, Heuck AF, Bruening R, Kohz P, Kimmig R, Stehling MK, Reiser MF.
Magnetic resonance imaging of the female pelvis. New circularly polarized body
array coil versus standard body coil.
Invest Radiol (1997);32(1):1-6
49. Hillemanns P, Thaler C, Kimmig R.
Epidemiology and diagnosis of cervical intraepithelial neoplasia--is the present
concept of screening and diagnosis still current?
Gynäkol Geburtsh. Rundsch (1997);37(4):179-91
50. Heuck A, Scheidler J, Kimmig R, Muller-Lisse U, Steinborn M, Helmberger T,
Reiser M.
Lymph node staging in cervix carcinomas: the results of high-resolution magnetic
resonance tomography (MRT) with a phased-array body coil.
Röfo (1997);166(3):210-4
51. Scheidler J, Heuck A, Wencke K, Kimmig R, Muller-Lisse U, Reiser M.
Parametrial infiltration of cervix carcinoma: diagnostic value of contrast-enhanced
fat-suppressed T1-weighted SE sequences at 1.5 tesla.
Röfo (1997);166(4):312-6

52. Hillemanns P, Kimmig R, Arnholdt H.
Conservative management of Sertoli-Leydig cell tumor of the ovary.
Acta Obstet Gynecol Scand (1997);76(6):604-7
53. Pfeiffer D, Spranger J, Al-Deiri M, Kimmig R, Fisseler-Eckhoff A, Scheidel P,
Schatz H, Jensen A, Pfeiffer A.
mRNA expression of ligands of the epidermal-growth-factor-receptor in the uterus.
Int J Cancer (1997); 7;72(4):581-6
54. Kimmig R, Pfeiffer D, Landsmann H, Hepp H.
Quantitative determination of the epidermal growth factor receptor in cervical
cancer and normal cervical epithelium by 2-color flow cytometry: evidence for
down-regulation in cervical cancer.
Int J Cancer (1997); 22;74(4):365-73
55. Kimmig R, Hillemanns P, Hepp H.
Die diagnostische Hysteroskopie – ein neuer Standard.
Gynäkologe (1997);30:384-91
56. Scheidler J, Heuck AF, Steinborn M, Kimmig R, Reiser MF.
Parametrial invasion in cervical carcinoma: evaluation of detection at MR imaging
with fat suppression.
Radiology (1998);206(1):125-9
57. Pfeiffer D, Kimmig R, Herrmann J, Ruge M, Fisseler-Eckhoff A, Scheidel P,
Jensen A, Schatz H, Pfeiffer A.
Epidermal-growth-factor receptor correlates negatively with cell density in cervical
squamous epithelium and is down-regulated in cancers of the human uterus.
Int J Cancer (1998);20;79(1):49-55
58. Loscar M, Schelling G, Haller M, Polasek J, Stoll C, Kreimeier U, Finsterer U,
Steitz HO, Baumeister R, Kimmig R, Grabein B, Briegel J.
Group A streptococcal toxic shock syndrome with severe necrotizing fasciitis
following hysterectomy--a case report.
Intensive Care Med (1998);24(2):190-3
59. Singer GA, Strowitzki T, Rettig I, Kimmig R.
Flow cytometric detection and binding studies of human endometrial stromal cell
epidermal growth factor receptor in monolayer culture: influence of progesterone.
Mol Hum Reprod (1998);4(6):577-83
60. Kimmig R, Strowitzki T, Hepp H.
Moderately differentiated endometrial carcinoma cured by conservative treatment.
Letter to the Editor.
Int J Gynecol Cancer (1998);8:511-2
61. Kimmig R, Seehaus D, Hillemanns P, Hepp H.
Hormonelle Substitution und Mammakarzinom. In: Diagnostik und Therapie des
Mammakarzinoms. State of the art. Untch M, Konecny G, Sittek H, Kessler M,
Reiser M, Hepp H (eds).
W Zuckschwerdt Verlag München Bern Wien New York (1998): S. 77-82
62. Kimmig R.
5. Recurrent cervical carcinoma – an invited comment.
Hungar J Gynecol Oncol (1998)

63. Hillemanns P, Korell M, Schmitt-Sody M, Baumgartner R, Beyer W, Kimmig R,
Untch M, Hepp H.
Photodynamic therapy in women with cervical intraepithelial neoplasia using
topically applied 5-aminolevulinic acid.
Int J Cancer (1999);31;81(1):34-8
64. Hillemanns P, Kimmig R, Huttemann U, Dannecker C, Thaler CJ.
Screening for cervical neoplasia by self-assessment for human papillomavirus
DNA.
Lancet (1999);4;354(9194):1970
65. Kimmig R.
Durchflußzytometrische DNA-Analyse solider gynäkologischer Tumoren nach
Zytokeratinmarkierung zur Detektion der Tumorzellen.
Habitationsschrift Ludwig-Maximilians-Universität München 1999
66. Kimmig R, Hillemanns P, Burges A, Hepp H.
Fertilitätserhaltung bei gynäkologischen Malignomen – Risikobezogene
Therapiestrategien. In: Neuerungen in der Onkologie. Utopie und Wirklichkeit?
Hrsg. Clemm Ch, Gutschow K.
W Zuckschwerdt Verlag ISBN 3-88603-669-3, (1999): S. 64-74
67. Hillemanns P, Kimmig R, Dannecker C, Noorzai T, Diebold J, Thaler CJ, Hepp H.
LEEP versus cold knife conization for treatment of cervical intraepithelial
neoplasias
Zentralbl Gynäkol (2000);122(1):35-42
68. Hillemanns P, Dannecker C, Kimmig R, Hasbargen U.
Obstetric risks and vertical transmission of hepatitis C virus infection in pregnancy.
Acta Obstet Gynecol Scand (2000);79(7):543-7
69. Kimmig R, Seehaus D, Hillemanns P, Hepp H.
Hormonelle Substitution und Mammakarzinom. In: Diagnostik und Therapie des
Mammakarzinoms. State of the art. Untch M. Konecny G, Sittek H, Kessler M,
Reiser M, Hepp H (eds.) 2 edn. (überarbeitete Auflage)
W Zuckschwerdt Verlag München Bern Wien New York (2000).
70. Sevelda P, Kimmig R.
Schwangerschaftsbedingte Trophoblasterkrankungen. In: Lehrbuch der Onkologie.
Hrsg. W. Hiddemann, München; Huber, Wien; Bartram, Heidelberg Springer
Verlag (2000)
71. Kimmig R, Hillemanns P, Hepp H.
Tibolon – eine Alternative zur Östrogensubstitution?
Gynäkologe (2000);33:408-15
72. Hillemanns P, Kimmig R, Hepp H.
Hormonale Substitution und extragenitale Neoplasien.
Gynäkologe (2000);33:416-22
73. Konecny G, Untch M, Pihan A, Kimmig R, Gropp M, Stieber P, Hepp H, Slamon
D, Pegram M.
Association of urokinase-type plasminogen activator and its inhibitor with disease
progression and prognosis in ovarian cancer.
Clin Cancer Res (2001);7(6):1743-9

74. Kimmig R, Wimberger P, Kapsner T, Hillemanns P.
Flow cytometric DNA analysis using cytokeratin labeling for identification of tumor
cells in carcinomas of the breast and the female genital tract.
Anal Cell Pathol (2001);22(3):165-78
75. Peiro G, Diebold J, Mayr D, Baretton GB, Kimmig R, Schmidt M, Lohrs U.
Prognostic relevance of hMLH1, hMSH2, and BAX protein expression in
endometrial carcinoma.
Mod Pathol (2001);14(8):777-83
76. du Bois A, Luck HJ, Pfisterer J, Schroeder W, Blohmer JU, Kimmig R, Moebus V,
Quaas J.
Second-line carboplatin and gemcitabine in platinum sensitive ovarian cancer--a
dose-finding study by the Arbeitsgemeinschaft Gynakologische Onkologie (AGO)
Ovarian Cancer Study Group.
Ann Oncol (2001);12(8):1115-20
77. Peiro G, Diebold J, Baretton GB, Kimmig R, Löhrs U.
Cellular apoptosis susceptibility gene expression in endometrial carcinoma:
correlation with Bcl-2, Bax, and caspase-3 expression and outcome.
Int J Gynecol Pathol (2001);20(4):359-67
78. Kimmig R, Wimberger P, Hillemanns P, Kapsner T, Caspari C, Hepp H.
Multivariate analysis of the prognostic significance of DNA-ploidy and S-phase
fraction in ovarian cancer determined by flow cytometry following detection of
cytokeratin-labeled tumor cells.
Gynecol Oncol (2002);84(1):21-31
79. Hasbargen U, Strauss A, Summerer-Moustaki M, Baretton G, Roth U, Kimmig R,
Hepp H.
Myomectomy as a pregnancy-preserving option in the carefully selected patient.
Fetal Diagn Ther (2002);17(2):101-3
80. Hasbargen U, Summerer-Moustaki M, Hillemanns P, Scheidler J, Kimmig R,
Hepp H.
Uterine dehiscence in a nullipara, diagnosed by MRI, following use of unipolar
electrocautery during laparoscopic myomectomy: Case report.
Hum Reprod (2002);17(8):2180-2
81. Otto T, Suhr J, Krege S, Goebell PJ, Wishahi M, Bier UW, Kimmig R, Rübben H.
Surgical treatment of disseminated peritoneal metastases from urological cancer:
results from a prospective study.
BJU Int (2002);90(9):823-7
82. Engel J, Eckel R, Schubert-Fritschle G, Kerr J, Kuhn W, Diebold J, Kimmig R,
Rehbock J, Hölzel D.
Moderate progress for ovarian cancer in the last 20 years: prolongation of survival,
but no improvement in the cure rate.
Eur J Cancer (2002);38(18):2435-45
83. Wimberger P, Hillemanns P, Kapsner T, Hepp H, Kimmig R.
Evaluation of prognostic factors following flow-cytometric DNA analysis after
cytokeratin labelling: I. Breast cancer.
Anal Cell Pathol (2002);24(4-5):135-45

84. Wimberger P, Hillemanns P, Kapsner T, Hepp H, Kimmig R.
Evaluation of prognostic factors following flow-cytometric DNA analysis after
cytokeratin labelling: II. Cervical and endometrial cancer.
Anal Cell Pathol (2002);24(4-5):147-58
85. Wimberger P, Xiang W, Mayr D, Diebold J, Dreier T, Baeuerle PA, Kimmig R.
Efficient tumor cell lysis by autologous, tumor-resident T lymphocytes in primary
ovarian cancer samples by an EP-CAM-/CD3-bispecific antibody.
Int J Cancer (2003);10;105(2):241-8
86. Oduncu FS, Kimmig R, Hepp H, Emmerich B.
Cancer in pregnancy: maternal-fetal conflict.
J Cancer Res Clin Oncol (2003);129(3):133-46
87. Xiang W, Wimberger P, Dreier T, Diebold J, Mayr D, Baeuerle PA, Kimmig R.
Cytotoxic activity of novel human monoclonal antibody MT201 against primary
ovarian tumor cells.
J Cancer Res Clin Oncol (2003);129(6):341-8
88. Kasimir-Bauer S, Otterbach F, Oberhoff C, Schmid KW, Kimmig R, Seeber S.
Rare expression of target antigens for immunotherapy on disseminated tumor cells
in breast cancer patients without overt metastases.
Int J Mol Med (2003);12(6):969-75
89. Schmitz KJ, Otterbach F, Callies R, Levkau B, Holscher M, Hoffmann O, Grabellus
F, Kimmig R, Schmid KW, Baba HA.
Prognostic relevance of activated Akt kinase in node-negative breast cancer: a
clinicopathological study of 99 cases.
Mod Pathol (2004);17(1):15-21
90. Hauth EA, Antoch G, Ruehm SG, Boing C, Kimmig R, Forsting M.
Value of pelvic MRI in the preoperative diagnosis of endometriosis.
Rofo (2004);176(9):1265-70
91. Kagan KO, Schmidt M, Kuhn U, Kimmig R.
Ventricular outflow obstruction, valve aplasia, bradyarrhythmia, pulmonary
hypoplasia and non-immune fetal hydrops because of a large rhabdomyoma in a
case of unknown tuberous sclerosis: a prenatal diagnosed cardiac rhabdomyoma
with multiple symptoms.
BJOG (2004);111(12):1478-80
92. Anthuber S, Hepp H, Fink D, Kimmig R, Lang U.
Contraception in young adolescents
Gynäkol Geburtsh. Rundsch (2005);45(4):223-4
93. Grabellus F, Worm K, Willruth A, Schmitz KJ, Otterbach F, Baba HA, Kimmig R,
Metz KA.
ETV6-NTRK3 gene fusion in a secretory carcinoma of the breast of a male-tofemale
transsexual.
Breast (2005);14(1):71-4

94. Schmitz KJ, Grabellus F, Callies R, Otterbach F, Wohlschlaeger J, Levkau B,
Kimmig R, Schmid KW, Baba HA.
High expression of focal adhesion kinase (p125FAK) in node-negative breast
cancer is related to overexpression of HER-2/neu and activated Akt kinase but
does not predict outcome.
Breast Cancer Res (2005);7(2):R194-203
95. Hauth EA, Stattaus J, Kimmig R, Schmidt M, Forsting M.
Magnetic resonance imaging (MRI) of the pelvis in diagnosing endometriosis.
Zentralbl Gynäkol (2005);127(2):76-82
96. Schlereth B, Fichtner I, Lorenczewski G, Kleindienst P, Brischwein K, da Silva A,
Kufer P, Lutterbuese R, Junghahn I, Kasimir-Bauer S, Wimberger P, Kimmig R,
Baeuerle PA.
Eradication of tumors from a human colon cancer cell line and from ovarian cancer
metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific
antibody construct.
Cancer Res (2005); 1;65(7):2882-9
97. Winter R, Kimmig R, Fink D.
Obstetric/Prenatal ultrasound: blessing or burden?
Gynäkol Geburtsh. Rundsch (2005);45(2):60-1
98. Heiss MM, Ströhlein MA, Jager M, Kimmig R, Burges A, Schoberth A, Jauch KW,
Schildberg FW, Lindhofer H.
Immunotherapy of malignant ascites with trifunctional antibodies.
Int J Cancer (2005); 10;117(3):435-43
99. Fink D, Kimmig R, Winter R.
Therapy of breast cancer-change from radical to quality-controlled individualized
treatment.
Gynäkol Geburtsh. Rundsch (2005);45(3):125-6
100.
101.
102.
103.
104.
Anthuber S, Hepp H, Fink D, Kimmig R, Lang U.
Contraception in young adolescents
Gynäkol Geburtsh. Rundsch (2005);45(4):223-4
Hauth EA, Antoch G, Stattaus J, Kuehl H, Veit P, Bockisch A, Kimmig R, Forsting
M.
Evaluation of integrated whole-body PET/CT in the detection of recurrent ovarian
cancer.
Eur J Radiol (2005);56(2):263-8
Kimmig R.
Treatment of ovarian cancer-an update.
MMW Fortschr Med (2005);27;147(43):25-6
Wimberger P, Kimmig R.
Surgical treatment of ovarian cancer
MMW Fortschr Med (2005); 27;147(43):31-3
Seeger D, Truong ST, Kimmig R.
Spontaneous delivery following tension-free vaginal tape procedure.
Int Urogynecol J Pelvic Floor Dysfunct (2005) 28:1-3

105.
106.
107.
108.
109.
110.
111.
112.
113.
Hahn S, Janssen OE, Tan S, Pleger K, Mann K, Schedlowski M, Kimmig R,
Benson S, Balamitsa E, Elsenbruch S.
Clinical and psychological correlates of quality-of-life in polycystic ovary syndrome.
Eur J Endocrinol (2005);153(6):853-60
Hauth EA, Wolfgarten B, Kimmig R, Forsting M.
MR imaging of the pelvis in characterization of adnexal masses
Zentralbl Gynäkol (2005);127(6):373-9
Hauth EA, Reiter K, Hoffmann O, Otterbach F, Kimmig R, Forsting M.
MR-guided vacuum assisted breast biopsy.
Zentralbl Gynäkol (2005);127(6):400-6
Kimmig R, Wimberger P.
Antikörpertherapien beim Ovarialkarzinom.
ArzneimForsch DrugRes (2005);55 (11):22-3
du Bois A, Burges A, Meier W, Pfisterer J, Schmalfeldt B, Richter B, Jackisch C,
Staehle A, Kimmig R, Elser G.
Pegylated liposomal doxorubicin and carboplatin in advanced gynecologic tumors:
a prospective phase I/II study of the Arbeitsgemeinschaft Gynaekologische
Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR).
Ann Oncol (2006);17(1):93-6
Schmitz KJ, Grabellus F, Callies R, Wohlschlaeger J, Otterbach F, Kimmig R,
Levkau B, Schmid KW, Baba HA.
Relationship and prognostic significance of phospho-(serine 166)-murine double
minute 2 and Akt activation in node-negative breast cancer with regard to p53
expression.
Virchows Arch (2006);448(1):16-23
Hahn S, Haselhorst U, Quadbeck B, Tan S, Kimmig R, Mann K, Janssen OE.
Decreased soluble leptin receptor levels in women with polycystic ovary
syndrome.
Eur J Endocrinol (2006);154(2):287-94
Wimberger P, Lehmann N, Kimmig R, Burges A, Meier W, Hoppenau B, du Bois
A; AGO-OVAR.
Impact of age on outcome in patients with advanced ovarian cancer treated within
a prospectively randomized phase III study of the Arbeitsgemeinschaft
Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
Gynecol Oncol (2006);100(2):300-7
Schmalfeldt B, du Bois A, Burges A, Emons G, Fink D, Gropp M, Hasenburg A,
Jager W, Kimmig R, Kiechle M, Kommoss F, Kreienberg R, Kuhn W, Luck HJ,
Meier W, Munstedt K, Ortmann O, Pfisterer J, Richter B, Runnebaum I, Schroder
W, Sehouli J, Tanner B, Wagner U, Weis J.
Diagnosis and treatment of malignant ovarian tumors 2005: recommendations of
the Kommission Ovar of the AGO.
Zentralbl Gynäkol (2006);128(1):11-7

114.
115.
116.
117.
118.
119.
120.
121.
122.
du Bois A, Weber B, Rochon J, Meier W, Goupil A, Olbricht S, Barats JC, Kuhn W,
Orfeuvre H, Wagner U, Richter B, Lueck HJ, Pfisterer J, Costa S, Schroeder W,
Kimmig R, Pujade-Lauraine E; Arbeitsgemeinschaft Gynaekologische Onkologie;
Ovarian Cancer Study Group; Groupe d'Investigateurs Nationaux pour l'Etude des
Cancers Ovariens.
Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment
of advanced ovarian cancer: a prospectively randomized gynecologic cancer
intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian
Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des
Cancers Ovariens.
J Clin Oncol (2006);1;24(7):1127-35
Hauth E, Libera H, Kimmig R, Forsting M.
MR Imaging of the pelvis in the diagnosis of the endometrium in breast cancer
patients in tamoxifen therapy.
Röfo (2006);178(3):316-23
Brischwein K, Schlereth B, Guller B, Steiger C, Wolf A, Lutterbuese R, Offner S,
Locher M, Urbig T, Raum T, Kleindienst P, Wimberger P, Kimmig R, Fichtner I,
Kufer P, Hofmeister R, da Silva AJ, Baeuerle PA.
MT110: a novel bispecific single-chain antibody construct with high efficacy in
eradicating established tumors.
Mol Immunol (2006);43(8):1129-43
Hauth EA, Reiter K., Kimmig R., Forsting M.
Die Magnetresonanztomographie (MRT)-gesteuerte Mamma-Vakuumbiopsie mit
dem Vacora®-System.
RöFo (2006); S1 178,VO 322.7
Hahn S, Bering van Halteren W, Roesler S, Schmidt M, Kimmig R, Tan S, Mann
K, Janssen OE.
The combination of increased ovarian volume and follicle number is associated
with more severe hyperandrogenism in German women with polycystic ovary
syndrome.
Exp Clin Endocrinol Diabetes (2006);114(4):175-81
Hauth EA, Kimmig R, Forsting M.
Magnetic resonance imaging (MRI) of the pelvis in the diagnosis of cervical
carcinoma – review.
Zentralbl Gynäkol (2006);128(2):60-7
Elsenbruch S, Benson S, Hahn S, Tan S, Mann K, Pleger K, Kimmig R, Janssen
OE.
Determinants of emotional distress in women with polycystic ovary syndrome.
Hum Reprod (2006);21(4):1092-9
Gellhaus A, Schmidt M, Dunk C, Lye SJ, Kimmig R, Winterhager E.
Decreased expression of the angiogenic regulators CYR61 (CCN1) and NOV
(CCN3) in human placenta is associated with pre-eclampsia.
Mol Hum Reprod (2006);12(6):389-99
Hauth EA, Stockamp C, Maderwald S, Muhler A, Kimmig R, Jaeger H,
Barkhausen J, Forsting M.
Evaluation of the three-time-point method for diagnosis of breast lesions in
contrast-enhanced MR mammography.
Clin Imaging (2006);30(3):160-5

123.
124.
125.
126.
127.
128.
129.
130.
131.
Fink D, Perucchini D, Lang U, Kimmig R.
Urinary incontinence and descensus genitalis--the silent sickness.
Gynäkol Geburts. Rundsch (2006);46(3):77-8
Hauth EA, Jaeger H, Maderwald S, Stockamp C, Muhler A, Kimmig R, Forsting
M.
Evaluation of quantitative parametic analysis for characterization of breast lesions
in constrast-enhanced MR mammography.
Eur Radiol (2006);29
Kimmig R, Fink D, Lang U.
Organ preservation, multimodal radical tumor therapy and reduction of therapyrelated
morbidity--development of diagnostics and therapy of endometrial
carcinoma.
Gynäkol Geburtsh. Rundsch (2006);46(1-2):1-2
Hahn S, Benson S, Elsenbruch S, Pleger K, Tan S, Mann K, Schedlowski M, van
Halteren WB, Kimmig R, Janssen OE.
Metformin treatment of polycystic ovary syndrome improves health-related qualityof-life,
emotional distress and sexuality.
Hum Reprod (2006);21(7):1925-34
Schmitz KJ, Callies R, Wohlschlaeger J, Kimmig R, Otterbach F, Bohr J, Lee HS,
Takeda A, Schmid KW, Baba HA.
Overexpression of cyclo-oxygenase-2 is an independent predictor of unfavourable
outcome in node-negative breast cancer, but is not associated with protein kinase
B (Akt) and mitogen-activated protein kinase (ERK1/2, p38) activation or with Her-
2/neu signalling pathways.
J Clin Pathol (2006);59(7):685-91
Böing C, Kimmig R.
Fertility-preserving treatment in young women with endometrial cancer.
Gynäkol Geburtsh. Rundsch (2006);46(1-2):25-33
Pfisterer J, Weber B, Reuss A, Kimmig R, du Bois A, Wagner U, Bourgeois H,
Meier W, Costa S, Blohmer JU, Lortholary A, Olbricht S, Stahle A, Jackisch C,
Hardy-Bessard AC, Mobus V, Quaas J, Richter B, Schroder W, Geay JF, Luck HJ,
Kuhn W, Meden H, Nitz U, Pujade-Lauraine E; AGO-OVAR; GINECO.
Randomized phase III trial of topotecan following carboplatin and paclitaxel in firstline
treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of
the AGO-OVAR and GINECO.
J Natl Cancer Inst (2006); 2;98(15):1036-45
Wimberger P., Kasimir-Bauer S, Weck B., Kimmig R.
Antikörpertherapien beim Ovarialkarzinom
Frauenarzt (2006); 10; 920 – 923
Pfisterer J., du Bois A, Sehouli J, Loibl S, Reinartz S, Reuss A, Canzler U, Belau
A, Jackisch C., Kimmig R., Wollschlaeger K, Heilmann V, Hilpert F.
The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer.
A phase I trial of the AGO-OVAR.
Ann Oncol. 2006 Oct;17(10):1568-1577.

132.
133.
134.
135.
136.
137.
138.
139.
140.
141.
Pfisterer J, Plante M, Vergote I, du Bois A, Hirte H, Lacave AJ, Wagner U, Stahle
A, Stuart G, Kimmig R, Olbricht S, Le T, Emerich J, Kuhn W, Bentley J, Jackisch
C, Luck HJ, Rochon J, Zimmermann AH, Eisenhauer E; AGO-OVAR; NCIC CTG;
EORTC GCG.
Gemcitabine plus carboplatin compared with carboplatin in patients with platinumsensitive
recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC
CTG, and the EORTC GCG.
J Clin Oncol. 2006 Oct 10;24(29):4699-707. 2006.
Schmidt M, Kimmig R.
[The benefits and risks of hormonal replacement therapy--an update]
Gynakol Geburtshilfliche Rundsch. 2006;46(4):166-73.
Schmidt M, Fink D, Lang U, Kimmig R.
[Hormone replacement therapy: curse or blessing?]
Gynakol Geburtshilfliche Rundsch. 2006;46(4):165
Hahn S, Haselhorst U, Tan S, Quadbeck B, Schmidt M, Roesler S, Kimmig R,
Mann K, Janssen OE.
Low serum 25-hydroxyvitamin D concentrations are associated with insulin
resistance and obesity in women with polycystic ovary syndrome.
Exp Clin Endocrinol Diabetes. 2006 Nov;114(10):577-83.
Otterbach F, Callies R, Frey UH, Schmitz KJ, Wreczycki C, Kimmig R, Siffert W,
Schmid KW.
The T393C polymorphism in the gene GNAS1 of G protein is associated with
survival of patients with invasive breast carcinoma.
Breast Cancer Res Treat. 2006 Dec 21;
Hauth EA, Khan K, Wolfgarten B, Betzler A, Kimmig R, Forsting M.
[Evaluation of the results after using of the BI-RADS categories in 1,777 clinical
mammograms.]
Radiologe. 2007 Jan 31;
Hahn S, Tan S, Sack S, Kimmig R, Quadbeck B, Mann K, Janssen OE.
Prevalence of the metabolic syndrome in german women with polycystic ovary
syndrome.
Exp Clin Endocrinol Diabetes. 2007 Feb;115(2):130-5.
Hahn S, Kuehnel W, Tan S, Kramer K, Schmidt M, Roesler S, Kimmig R, Mann K,
Janssen OE.
Diagnostic value of calculated testosterone indices in the assessment of polycystic
ovary syndrome.
Clin Chem Lab Med. 2007;45(2):202-7.
Lang U, Fink D, Kimmig R.
[Multiple pregnancies]
Gynakol Geburtshilfliche Rundsch. 2007;47(1):1-2
Kummel S, Rezai M, Kimmig R, Schmid P.
Dose-dense chemotherapy for primary breast cancer.
Curr Opin Obstet Gynecol. 2007 Feb;19(1):75-81.

142.
143.
144.
145.
146.
147.
148.
149.
150.
151.
152.
Matuszczyk A, Petersenn S, Lahner H, Haude M, Veit P, Becker JU, Kimmig R,
Bockisch A, Mann K.
Leydig cell tumor as a cause of hirsutism in a postmenopausal woman.]
Med Klin (Munich). 2007 Mar 15;102(3):259-62.
Wimberger P, Lehmann N, Kimmig R, Burges A, Meier W, Du Bois A;
Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group.
Prognostic factors for complete debulking in advanced ovarian cancer and its
impact on survival. An exploratory analysis of a prospectively randomized phase III
study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer
Study Group (AGO-OVAR).
Gynecol Oncol. 2007 Jul;106(1):69-74. 2007 Mar 29.
Lang U, Fink D, Kimmig R.
[Multiple pregnancies--Part 2]
Gynakol Geburtshilfliche Rundsch. 2007;47(2):55-6.
Burges A, Wimberger P, Kumper C, Gorbounova V, Sommer H, Schmalfeldt B,
Pfisterer J, Lichinitser M, Makhson A, Moiseyenko V, Lahr A, Schulze E, Jager M,
Strohlein MA, Heiss MM, Gottwald T, Lindhofer H, Kimmig R.
Effective relief of malignant ascites in patients with advanced ovarian cancer by a
trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study.
Clin Cancer Res. 2007 Jul 1;13(13):3899-905.
Fink D, Lang U, Kimmig R.
[Endometriosis—a frequently underestimated disease]
Gynakol Geburtshilfliche Rundsch. 2007;47(3):111-2.
Boing C, Kimmig R.
[Surgical management of endometriosis--an overview]
Gynakol Geburtshilfliche Rundsch. 2007;47(3):124-31.
Hauth EA, Jaeger HJ, Maderwald S, Muehler A, Kimmig R, Forsting M.
Quantitative 2- and 3-dimensional analysis of pharmacokinetic model-derived
variables for breast lesions in dynamic, contrast-enhanced MR mammography.
Eur J Radiol. 2007 Jul 18;
Hahn S, Backhaus M, Broecker-Preuss M, Tan S, Dietz T, Kimmig R, Schmidt M,
Mann K, Janssen OE.
Retinol-binding protein 4 levels are elevated in polycystic ovary syndrome women
with obesity and impaired glucose metabolism.
Eur J Endocrinol. 2007 Aug;157(2):201-7.
Kimmig R.
[Vaccination against human papilloma virus. Has cervical cancer been beaten?]
MMW Fortschr Med. 2007 Mar 22;149(12):28-9.
Böing C, Kimmig R.
[Stage-adapted treatment of cervical carcinoma]
MMW Fortschr Med. 2007 Mar 22;149(12):32-4.
Schmidt M, Kimmig R, Kasimir-Bauer S, et al.
Determination of serum PLGF by ELISA in normal and preeclamptic pregnancies.
CLINICAL CHEMISTRY 53 (6): A209-A209 D155 Suppl. S JUN 2007

153.
154.
155.
156.
157.
158.
159.
160.
161.
Mobus V, Wandt H, Frickhofen N, Bengala C, Champion K,
Kimmig R, Ostermann H, Hinke A, Ledermann JA.
High-Dose Sequential Chemotherapy With Peripheral Blood
Stem Cell Support Compared With Standard Dose
Chemotherapy for First-Line Treatment of Advanced Ovarian
Cancer: Results of a Phase III Intergroup Trial of the AGO-
Ovar/AIO and EBMT.
J Clin Oncol. 2007 Aug 13;
Mobus V, Wandt H, Frickhofen N, Bengala C, Champion K, Kimmig R, Ostermann
H, Hinke A, Ledermann JA; AGO-Ovar/AIO; EBMT.
Phase III trial of high-dose sequential chemotherapy with peripheral blood stem
cell support compared with standard dose chemotherapy for first-line treatment of
advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT.
J Clin Oncol. 2007 Sep 20;25(27):4187-93. 2007 Aug 13.
Wimberger P, Heubner M, Otterbach F, Fehm T, Kimmig R, Kasimir-Bauer S.
Influence of platinum-based chemotherapy on disseminated tumor cells in blood
and bone marrow of patients with ovarian cancer.
Gynecol Oncol. 2007 Aug 30;
Bachmann HS, Otterbach F, Callies R, Nuckel H, Bau M, Schmid KW, Siffert W,
Kimmig R.
The AA Genotype of the Regulatory BCL2 Promoter Polymorphism ( 938C>A) Is
Associated with a Favorable Outcome in Lymph Node Negative Invasive Breast
Cancer Patients.
Clin Cancer Res. 2007 Oct 1;13(19):5790-7.
Schmidt M, Fink D, Lang U, Kimmig R.
[Hypertensive diseases during pregnancy: an interdisciplinary challenge]
Gynakol Geburtshilfliche Rundsch. 2007;47(4):197-8.
Schmidt M, Kimmig R.
[Pathophysiology of preeclampsia]
Gynakol Geburtshilfliche Rundsch. 2007;47(4):199-204.
Hauth EA, Kimmig R, Forsting M.
[Diagnosis of vulval and vaginal neoplasms with magnetic resonance imaging]
Gynakol Geburtshilfliche Rundsch. 2007;47(4):226-35.
Fechner S, Husen B, Thole H, Schmidt M, Gashaw I, Kimmig R, Winterhager E,
Grummer R.
Expression and regulation of estrogen-converting enzymes in ectopic human
endometrial tissue.
Fertil Steril. 2007 Oct;88(4 Suppl):1029-38. 2007 Feb 20.
Tan S, Hahn S, Benson S, Dietz T, Lahner H, Moeller LC, Schmidt M, Elsenbruch
S, Kimmig R, Mann K, Janssen OE.
Metformin improves polycystic ovary syndrome symptoms irrespective of pretreatment
insulin resistance.
Eur J Endocrinol. 2007 Nov;157(5):669-76.

162.
163.
164.
165.
166.
167.
168.
169.
170.
171.
172.
Schmidt M, Dogan C, Birdir C, Callies R, Kuhn U, Gellhaus A, Janetzko A,
Kimmig R, Kasimir-Bauer S.
Altered angiogenesis in preeclampsia: evaluation of a new test system for
measuring placental growth factor.
Clin Chem Lab Med. 2007;45(11):1504-10.
Hauth EA, Jaeger H, Maderwald S, Mühler A, Kimmig R, Forsting M.
[Quantitative parametric analysis of contrast-enhanced lesions in dynamic MR
mammography.]
Radiologe. 2008 Jun;48(6):593-600.
Gashaw I, Stiller S, Böing C, Kimmig R, Winterhager E.
Pre-menstrual regulation of the pro-angiogenic factor CYR61 in human
endometrium.
Endocrinology. 2008 May;149(5):2261-9.
Kimmig R, Fink D, Lang U.
[Physical integrity versus oncological safety: synthesis of important aspects in the
treatment of breast cancer]
Gynakol Geburtshilfliche Rundsch. 2008;48(2):55.
Kramer S, Darsow M, Kummel S, Kimmig R, Rezai M.
Breast-conserving treatment of breast cancer--oncological and reconstructive
aspects.
Gynakol Geburtshilfliche Rundsch. 2008;48(2):56-62.
Blohmer JU, Kimmig R, Kummel S, Costa SD, Kramer S, Rezai M.
[Intraoperative radiotherapy of breast cancer]
Gynakol Geburtshilfliche Rundsch. 2008;48(2):63-7.
Hauth EA, Hoffmann O, Zadow-Eulerich T, Kimmig R, Forsting M.
[Magnetic resonance tomography in the diagnostics of breast implants: a survey]
Gynakol Geburtshilfliche Rundsch. 2008;48(2):76-83.
Kummel S, Heidecke H, Brock B, Denkert C, Hecktor J, Koninger A, Becker I,
Sehouli J, Thomas A, Blohmer JU, Lichtenegger W, Kimmig R.
[Imatinib--a possible therapeutic option for cervical carcinoma: results of a
preclinical phase I study]
Gynakol Geburtshilfliche Rundsch. 2008;48(2):94-100.
Schmidt M, Hoffmann B, Beelen D, Gellhaus A, Winterhager E, Kimmig R,
Kasimir-Bauer S.
Detection of circulating trophoblast particles in peripheral maternal blood in
preeclampsia complicated pregnancies.
Hypertens Pregnancy. 2008;27(2):131-42.
Fink D, Lang U, Kimmig R.
[Fundamental advances in the adjuvant systemic therapy of breast cancer]
Gynakol Geburtshilfliche Rundsch. 2008;48(3):111-2.
Tan S, Hahn S, Benson S, Janssen OE, Dietz T, Kimmig R, Hesse-Hussain J,
Mann K, Schedlowski M, Arck PC, Elsenbruch S.
Psychological implications of infertility in women with polycystic ovary syndrome.
Hum Reprod. 2008 Sep.;23(9):2064-71.

173.
174.
175.
176.
177.
178.
179.
180.
181.
182.
183.
184.
Hauth EA, Jaeger HJ, Lubnau J, Maderwald S, Otterbach F, Kimmig R, Forsting
MR-guided vacuum-assisted breast biopsy with a handheld biopsy system: clinical
experience and results in postinterventional MR mammography after 24 h.
Eur Radiol. 2008;18(1): 168-76
Allhorn S, Böing C, Koch AA, Kimmig R, Gashaw
TLR3 and TLR4 expression in healthy and diseased human endometrium.
Reprod Biol Endocrinol. 2008 Sep 7;6(1):40.
Köninger A, Kümmel S, Kimmig R.
[Hormone replacement therapy in patients after breast cancer]
MMW Fortschr Med. 2008 Oct 23;150(43):32-4.
Nierwetberg D, Schmidt M, Kimmig R.
[Hormone replacement therapy and cancer risk]
MMW Fortschr Med. 2008 Oct 23;150(43):27-8.
Wimberger, P, Welt A, Kimmig R.
Infertilität: Prophylaxe und Behandlung
Supportive Therapie in der Onkologie 2008 11/2008 463-475.
Birdir C, Callies R, Schmidt M, Stein A, Kimmig R
Tuberculosis pericarditis constrictive in the pregnancy - A Case report
Geburtshilfe Frauenheilkd. 2008;68(3): 310-310
Distler W, Beckmann MW, Kimmig R, Runnebaum I, Eiermarnn W
ATAC-Study: 100 months lasting analyze shows that after therapy ending
considered effectiveness of Anastrozol versus Tamoxifen Carry-over-Effect
benefits in adjustment of fractured rat in Arimidex, Tamoxifen, Alone or in
Combination (ATAC)-Study
Geburtshilfe Frauenheilkd. 2008;68 Suppl. : S30-S30
Hauth EA, Umutlu L, Quinsten A, Kummel S, Kimmig R, Forsting M
MR-guided vacuum assisted breast biopsy with the ATEC (R) breast biopsy and
excision system
Geburtshilfe Frauenheilkd. 2008;68(9): 901-906
Hilpert F, Harter P, Wimberger P, Kimmig R, Pfisterer J, du Bois A
Treatment of elderly patients with advanced ovarian cancer in the context of
controlled clinical trials - A joint analysis of 3 AGO-Ovar subprojects
Geburtshilfe Frauenheilkd. 2008;68 Suppl. : S13-S13
Lang U, Fink D, Kimmig R.
Fetal programming]
Gynakol Geburtshilfliche Rundsch. 2008;48(4):205-6. .
Otterbach F, Callies R, Kimmig R, Schmid KW, Bánkfalvi A.
Aquaporin 1 expression in invasive breast carcinomas]
Pathologe. 2008 Nov;29 Suppl 2:357-62.
M.W. Beckmann, G. Emons, R. Kimmig, P. Mallmann
AGO: Aktuelles aus S2 k-Leitlinien zur Diagnostik und Therapie des
Endometriumkarzinoms und des Zervixkarzinoms
Forum 2 2008 Deutsche Krebsgesellschaft e.V.

185.
186.
187.
188.
189.
190.
191.
192.
193.
194.
195.
Wimberger P, Kimmig R.
The role of radical lymphadenectomy: Experiences from the AGO Ovarian Cancer
Study Group.
Urologe A. 2009 Jan; 48 (1):26-31.2008 Dec 7
B. Aktas, M. Tewes, S. Hauch, R. Kimmig, S. Kasimir-Bauer
Zirkulierende Tumorzellen beim metastasierten Mammakarzinom
Med Review 02/2009, S 3 - 4
Heubner M, Riemann K, Otterbach F, Kimmig R, Kasimir-Bauer S, Siffert W,
Wimberger P.
The haplotype of two FSHR polymorphisms in ovarian cancer- A potential role of
ethnology in risk modification.
Gynecol Oncol. 2009 Mar; 112 (3): 486-9.
Kenemans P, Bundred NJ, Foidart JM, Kubista E, von Schoultz B, Sismondi P,
Vassilopoulou-Sellin R, Yip CH, Egberts J, Mol-Arts M, Mulder R, van Os S,
Beckmann MW; LIBERATE Study Group.
Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms:
a double-blind, randomised, non-inferiority trial.
Lancet Oncol. 2009 Feb;10(2):135-46.
Lang U, Fink D, Kimmig R.
Intrauterine programming of specific organ systems]
Gynakol Geburtshilfliche Rundsch. 2009;49(1):1.
Schmidt M, Callies R, Kuhn U, Willruth A, Kimmig R.
External cephalic version in cases of breech presentation: renaissance of a wellknown
procedure?
Gynakol Geburtshilfliche Rundsch. 2009;49(1):29-34.
Hauth EA, Umutlu L, Libera H, Kimmig R, Forsting M.
Magnetic resonance imaging of the pelvis in patients with polycystic ovary
syndrome
Rofo. 2009 Jun;181(6):543-8.
Imthurn B, Kimmig R, Lang U, Fink D.
New developments in reproductive medicine
Gynakol Geburtshilfliche Rundsch. 2009;49(2):53-4.
Schmidt M, Dogan C, Birdir C, Kuhn U, Gellhaus A, Kimmig R, Kasimir-Bauer S.
Placental growth factor: a predictive marker for preeclampsia?
Gynakol Geburtshilfliche Rundsch. 2009;49(2):94-9.
Emons G, Kimmig R.
Interdisciplinary S2k guidelines on the diagnosis and treatment of endometrial
carcinoma.
J Cancer Res Clin Oncol. 2009 Oct;135(10):1387-91.
Wimberger P, Heubner M, Lindhofer H, Jäger M, Kimmig R, Kasimir-Bauer S.
Influence of catumaxomab on tumor cells in bone marrow and blood in ovarian
cancer.
Anticancer Res. 2009 May;29(5):1787-91.

196.
197.
198.
199.
200.
201.
202.
203.
204.
205.
Schmidt M, Hoffmann B, Kimmig R, Kasimir-Bauer S.
mRNA of Placental Origin in Maternal Serum of Women with Normal and
Preeclamptic Pregnancies.
Fetal Diagn Ther. 2009 Jun 11;25(2):269-276
Fink D, Lang U, Kimmig R.
Use of laparoscopy in gynecological oncology
Gynakol Geburtshilfliche Rundsch. 2009;49(3):109-10.
Wimberger P, Kimmig R.
Significance of laparoscopy in gynaecological oncology: limitations for adnexal
tumours
Gynakol Geburtshilfliche Rundsch. 2009;49(3):133-7.
Tewes M, Aktas B, Welt A, Mueller S, Hauch S, Kimmig R, Kasimir-Bauer S.
Molecular profiling and predictive value of circulating tumor cells in patients with
metastatic breast cancer: an option for monitoring response to breast cancer
related therapies.
Breast Cancer Res Treat. 2009 Jun;115(3):581-90.
Aktas B, Tewes M, Fehm T, Hauch S, Kimmig R, Kasimir-Bauer S.
Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed
in circulating tumor cells of metastatic breast cancer patients.
Breast Cancer Res. 2009 Jul 9;11(4):R46.
Meier W, du Bois A, Reuss A, Kuhn W, Olbricht S, Gropp M, Richter B, Lück HJ,
Kimmig R, Pfisterer J
Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian
cancer and relapse within 12 months following 1st-line platinum/paclitaxel
chemotherapy. A prospectively randomized phase III trial by the
Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group
(AGO-OVAR).
Gynecol Oncol. 2009 Aug;114(2):199-205.
Untch, M., Beckmann, MW, Emons, G., Thomssen C., Kimmig R.
The LIBERATE Study: Hormone Replacement Therapy with Tibolone Increases
the Risk of Recurrence and Metastases in Breast Cancer Patients
Geburtshilfe Frauenheilkd. 2009;69(3): 199-201
Untch M., Beckmann MW.,Emons G., Thomssen Ch, Kimmig R
Tibolon erhöht das Rezidivrisiko bei Mammakarzinompatientinnen – neueste
Daten aus der LIBERATE-Studie.
Frauenheilkunde up2date 2009;3 (6) 168-172
Heubner M, Wimberger P, Kasimir-Bauer S, Otterbach F, Kimmig R, Siffert W.
The AA genotype of a L1C G842A polymorphism is associated with an increased
risk for ovarian cancer.
Anticancer Res. 2009 Aug;29(8):3449-52.
Fehm T, Hoffmann O, Aktas B, Becker S, Solomayer EF, Wallwiener D, Kimmig
R, Kasimir-Bauer S.
Detection and characterization of circulating tumor cells in blood of primary breast
cancer patients by reverse-transcriptase polymerase chain reaction and
comparison to status of bone marrow disseminated cells.
Breast Cancer Res. 2009 Aug 10;11(4):R59.

206.
207.
208.
209.
210.
211.
212.
213.
214.
215.
Mönckedieck V, Sannecke C, Husen B, Kumbartski M, Kimmig R, Tötsch M,
Winterhager E, Grümmer R.
Progestins inhibit expression of MMPs and of angiogenic factors in human ectopic
endometrial lesions in a mouse model.
Mol Hum Reprod. 2009 Oct;15(10):633-43. 2009 Aug 11.
P. Wimberger, R. Kimmig
Gynäkologische Malignome - Das Sentinelkonzept ist nicht immer geeignet
Info Onkologie 02/2009, S. 37 - 41
Schwarzenbach H, Pantel K, Kemper B, Beeger C, Otterbach F, Kimmig R,
Kasimir-Bauer S.
Comparative evaluation of cell-free tumor DNA in blood and disseminated tumor
cells in bone marrow of patients with primary breast cancer.
Breast Cancer Res. 2009 Sep 21;11(5):R71.
Erim Y, Beckmann M, Gerlach G, Kümmel S, Oberhoff C, Senf W, Kimmig R.
[Screening for distress in women with breast cancer diagnosed for the first time:
employment of HADS-D and PO-Bado]
Z Psychosom Med Psychother. 2009;55(3):248-62. German.
P. Wimberger, P. Sevelda, R. Kimmig
Schwangerschaftsbedingte Trophoblasttumoren
Die Onkologie 2. Auflage, Teil 2, 2009;1022 – 1037
Wimberger P. Schröder W. Kimmig R.
Epitheliales Ovarialkarzinom. Neue molekularbiologische Ansätze
Management des Ovarialkarzinoms Hrsg. Kreienberg et. Al
Springer Verlag 2009; S. 218-230; ISBN 978-3-540-41987-7.
Hoffmann O, Solomayer E, Kuemmel S, Hahn M, Kasimir-Bauer S.), Kimmig R,
Wallwiener D, Fehm T.
Does Primary Systemic Therapy Erradicate Disseminated and Circulating Tumor
Cells?
Cancer Research 2009;69 Suppl. 24: 647 S-647 S
Heubner M, Wimberger P, Otterbach F, Kasimir-Bauer S, Siffert W, Kimmig R,
Nuckel H.
Association of the AA genotype of the BCL2 (-938C>A) promoter polymorphism
with better survival in ovarian cancer.
Int J Biol Markers. 2009 Oct-Dec;24(4):223-9.
Tan S, Scherag A, Janssen OE, Hahn S, Lahner H, Dietz T, Scherag S, Grallert H,
Vogel CI, Kimmig R, Illig T, Mann K, Hebebrand J, Hinney A.
Large effects on body mass index and insulin resistance of fat mass and obesity
associated gene (FTO) variants in patients with polycystic ovary syndrome
(PCOS).
BMC Med Genet. 2010 Jan 21;11(1):12.
Otterbach F, Callies R, Adamzik M, Kimmig R., Siffert W, Schmid KW, Bankfalvi A
Aquaporin 1 (AQP1) expression is a novel characteristic feature of a particularly
aggressive subgroup of basal-like breast carcinomas
BREAST CANCER RESEARCH AND TREATMENT 2010;120 (1):67-76

216.
217.
218.
219.
220.
221.
222.
223.
224.
225.
226.
Wimberger P, Wehling M, Lehmann N, Kimmig R, Schmalfeldt B, Burges A,
Harter P, Pfisterer J, du Bois A.
Influence of Residual Tumor on Outcome in Ovarian Cancer Patients with FIGO
Stage IV Disease: An Exploratory Analysis of the AGO-OVAR
(Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group).
Ann Surg Oncol. 2010 Jun;17(6):1642-8. 2010 Feb 18.
Heubner M, Wimberger P, Riemann K, Kasimir-Bauer S, Otterbach F, Kimmig R,
Siffert W.
The CYP1A1 Ile462Val polymorphism and platinum resistance of epithelial ovarian
neoplasms.
Oncol Res. 2010;18(7):343-7.
Barbara Mikat, Rainer Kimmig, Markus Schmidt
Diagnostik und Therapie der Präeklampsie – State of the Art
Gynäkologie 2010
Landt S, Sina F, Kimmig R, Schmidt M.
[H1N1--pregnancy as risk factor]
Z Geburtshilfe Neonatol. 2010 Apr;214(2):48-51. 2010 Apr 21. German.
Hauth E, Umutlu L, Kümmel S, Kimmig R. et al
Follow-up of Probably Benign Lesions (BI-RADS 3 category) in Breast MR Imaging
Breast Journal 2010 May-Jun;16(3) 297-304
Grabellus F, Sheu SY, Bachmann HS, Lehmann N, Otterbach F, Heusner TA,
Antoch G, Bockisch A, Kimmig R, Schmid KW, Stahl AR.
The XbaI G>T polymorphism of the glucose transporter 1 gene modulates 18F-
FDG uptake and tumor aggressiveness in breast cancer.
J Nucl Med. 2010 Aug;51(8):1191-7.
Mensah J, Kimmig R, Schmidt M.
Ovarian Hyperstimulation Syndrome in an Aneuploid Pregnancy
Geburtshilfe und Frauenheilkunde 2010 Oct.; 70 (10): 828-831.
Goldnau C., Köninger A, Kimmig R.
[The female external genitalia: Pathologic findings and first steps in treatment.]
Urologe A. 2010 Dec;49(12):1496-502.
Heubner M, Wimberger P, Dahlmann B, Kasimir-Bauer S, Kimmig R, Peters J,
Wohlschlaeger J, Sixt SU.
The prognostic impact of circulating proteasome concentrations in patients with
epithelial ovarian cancer.
Gynecol Oncol. 2011 Feb;120(2):233-8.
Wimberger P, Roth C, Pantel K, Kasimir-Bauer S, Kimmig R, Schwarzenbach H.
Impact of platinum-based chemotherapy on circulating nucleic acid levels,
protease activities in blood and disseminated tumor cells in bone marrow of
ovarian cancer patients.
Int J Cancer. 2011 Jun 1; 128(11):2572-80.doi:10.1002/ijc.25602.Epub 2010 Oct.
Heubner M, Errico D, Kasimir-Bauer S, Herlyn D, Kimmig R, Wimberger P.
EpCAM-autoantibody levels in the course of disease of ovarian cancer patients.
Med Oncol. 2011 Jun;28(2):626-30.Epub 2010 Apr.

227.
228.
229.
230.
231.
232.
233.
234.
235.
Kurtz JE, Kaminsky MC, Floquet A, Veillard AS, Kimmig R, Dorum A, Elit L, Buck
M, Petru E, Reed N, Scambia G, Varsellona N, Brown C, Pujade-Lauraine E; on
behalf of Gynecologic Cancer Intergroup.
Ovarian cancer in elderly patients: carboplatin and pegylated liposomal
doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic
Cancer Intergroup (GCIG) CALYPSO sub-study.
Ann Oncol. 2011 Mar 14.
Kimmig in: Janni W., Maass, N.
Robotic Surgery in der Gynäkologie – Chirurgie der Zukunft oder teurer PR-Gag?
Der Gynäkologe 5/2011; 401-404
Kuhlmann JD, Schwarzenbach H, Otterbach F, Heubner M, Wimberger P, Worm
KH, Kimmig R, Kasimir-Bauer S.
Loss of heterozygosity proximal to the M6P/IGF2R locus is predictive for the
presence of disseminated tumor cells in the bone marrow of ovarian cancer
patients before and after chemotherapy.
Genes Chromosomes Cancer. 2011 Aug;50(8):598-605. doi: 10.1002/gcc.20882.
Epub 2011 May 11.
Erim Y, Beckmann M, Hoffmann O, Wimberger, P., Kimmig, R.
Predictors of Psychological Stress in Breast Cancer Patients - What Should
Physicians and Nursing Staff Pay Attention to in an Oncological Setting?
Geburtshilfe und Frauenheilkunde 2011 Apr.2011; 71 (4), 285-291.
Cibula D, Verheijen R, Lopes A, Amant F, Beller U, Colombo N, Gitsch G, Kesic V,
Kimmig R, Markowska J, Marth C, Reed N, Rodolakis A, Salvesen H, Vaitkiene D,
van der Zee AG, Zola P.
Training in Bowel and Upper Abdominal Surgery in Gynaecological Oncology:
European Society of Gynecological Oncology (ESGO) Statement.
Int J Gynecol Cancer. 2011 Jun 28.
Sauerwein W, Hoffmann O., Schütte, M., Aktas B., Abu Jawad J., Stuschke, M.
Kimmig R.
Intraoperative Irradiation of the Tumor bed as a Boost in the Burst-sustaining
Primary treatment of Breast cancer - Initial results and issues that arises
Strahlentherapie und Onkologie 2011;187 (Suppl.1):99-100.
Hoffmann O, Heubner M, Anlasik T, Winterhalter M, Dahlmann B, Kasimir-Bauer
S, Kimmig R, Wohlschlaeger J, Sixt SU.
Circulating 20S Proteasome in Patients with Non-metastasized Breast Cancer.
Anticancer Res. 2011 Jun;31(6):2197-201.
Heinrich B; Komitee für Praktische Onkologie.
[Asbestos-induced diseases: an on-going problem].
MMW Fortschr Med. 2011 Jun 2;153(22):34.
Aktas B, Kasimir-Bauer S, Heubner M, Kimmig R, Wimberger P.
Molecular profiling and prognostic relevance of circulating tumor cells in the blood
of ovarian cancer patients at primary diagnosis and after platinum-based
chemotherapy.
Int J Gynecol Cancer. 2011 Jul;21(5):822-30.